FDA Clears  Novel Multi-Point Nerve Disruption Treatmen

GALWAY, Ireland - The Food and Drug Administration (FDA) has cleared Neuromark™ Rhinitis Neurolysis Therapy™ which is first in-office treatment indicated to disrupt symptom-causing posterior nasal...

Related Keywords

United States , Americans , , Marc Dubin , Scientific Advisor , Neurent Medical , Food And Drug Administration , Rhinitis Neurolysis Therapy ,